A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a ...

Roche has waved goodbye to an inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid for the therapy—as part of a ...

The Swiss drugmaker expects sales and core earnings per share to grow at constant currencies this year, partly due to the strength of its drug pipeline.

Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies this quarter.

BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...

Roche Holding (SWX:ROG) reported significant weight loss results from Phase II trials of its dual GLP-1/GIP obesity candidate CT-388. The company plans protocol adjustments for upcoming Phase III ...

Roche aims to become a “top three player” in obesity, Teresa Graham, CEO of the group’s Pharma unit, said Thursday during a ...

Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of ...

Roche’s Genentech plans to start its Phase 3 this quarter, but primary completion will happen by 2028. Click here to find out ...

A late-stage trial of CT-388 is expected to start this quarter.

Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as ...

Roche’s CT-388 phase 2 obesity results show 22.5% weight loss and solid tolerability vs tirzepatide—plus what’s next for ...